Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-12
2011-07-12
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07977310
ABSTRACT:
This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.
REFERENCES:
patent: 1125560 (2001-08-01), None
patent: WO 01/80852 (2001-11-01), None
patent: WO 02/34259 (2002-05-01), None
Yki-Järvinen et al. “Less Nocturnal Hypoglycemia and Better Post-Dinner Glucose Control With Bedtime Insulin Glargine Compared With Bedtime NPH Insulin During Insulin Combination Therapy in Type 2 Diabetes,” Diabetes Care, 2000, 23, 1130-1136.
Costa, A., et. al., Impaired Glucose Tolerance, Treat Endocrinol. 2002, vol. 1, pp. 205-210.
Nathan, D.M., et. al., Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for Care, Diabetes Care, 2007, 30(3), pp. 753-759.
Rosenstock, J., et. al., Basal Insulin Therapy in Type 2 Diabetes: 28-week Comparison of Insulin Glargine (HOE 901) and NPH Insulin, Abstract XP002282639 Medline, Diabetes Care Apr. 2001, vol. 24, No. 4, pp. 631-636.
Thomas, M., et. al. Evaluation of the Safety, Efficacy and Tolerability of Insulin Glargine in Subjects with Impaired fasting Glucose, Impaired Glucose Tolerance or New-Onset Type 2 Diabetes, Abstract Biosis/Biosis vol. 52, No. Supplement 1, 2003 pp. A451-A452 XP002282638.
Turner,R., et. al. Beta-Cell function Improved by Supplementing Basal Insulin Secretion in Mild Diabetes, British Medical Journal May 22, 1976, vol. 1, No. 6020, pp. 1252-1254 XP009031347.
Mooradian, A. D., et. al. , Cardiovascular Disease in Type 2 Diabetes Mellitus, Archives Internal Med., vol. 163, No. 1, pp. 33-40, (2003).
Gerstein Hertzel
Rosskamp Ralf
Aventis Pharmaceuticals Inc.
Bradley Christina
Loewrick Oliver
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Method for reducing cardiovascular morbidity and mortality... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing cardiovascular morbidity and mortality..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing cardiovascular morbidity and mortality... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2653010